Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL

2010 ◽  
Vol 92 (5) ◽  
pp. 732-743 ◽  
Author(s):  
Dai Maruyama ◽  
Takashi Watanabe ◽  
Akiko Miyagi Maeshima ◽  
Junko Nomoto ◽  
Hirokazu Taniguchi ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Adult Patients ◽  
Japanese Adult ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

2020 ◽  
Vol 25 (9) ◽  
pp. 1736-1743
Author(s):  
Hideki Goto ◽  
Shinichi Makita ◽  
Koji Kato ◽  
Kota Tokushige ◽  
Taizo Fujita ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Adult Patients ◽  
Efficacy And Safety ◽  
Japanese Adult ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Should Adolescents with NHL Be Treated as Old Children or Young Adults?

Hematology ◽  
2007 ◽  
Vol 2007 (1) ◽  
pp. 297-303 ◽  
Author(s):  
John T. Sandlund
Keyword(s):  
Young Adults ◽  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoblastic Lymphoma ◽  
Adolescents And Young Adults ◽  
Large B Cell Lymphoma ◽  
Age Related ◽  
Large B Cell

Abstract The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975–1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults. Many factors may contribute to this age-related difference. Some factors are related to the patient (e.g., drug distribution and clearance, performance status, compliance, sex) whereas others pertain to tumor histology and biology. The spectrum of NHL subtypes is well known to differ in children and adults. From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range. Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial. It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma). However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma. There is clearly a need for further biologic study of NHL in children, adolescents, and young adults. Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL). Additional biologic data will not only improve prognosis and treatment stratification but, more important, will lead to the identification of specific molecular targets for therapy.

scholarly journals The Distinction between Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma with c-myc Rearrangement

2002 ◽  
Vol 15 (7) ◽  
pp. 771-776 ◽  
Author(s):  
Naoya Nakamura ◽  
Hirokazu Nakamine ◽  
Jun-ichi Tamaru ◽  
Shigeo Nakamura ◽  
Tadashi Yoshino ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica ◽  
2017 ◽  
Vol 102 (7) ◽  
pp. 1247-1257 ◽  
Author(s):  
Richard A. Noble ◽  
Natalie Bell ◽  
Helen Blair ◽  
Arti Sikka ◽  
Huw Thomas ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Therapeutic Approach ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Novel Therapeutic

scholarly journals A Case of B-cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma in a Korean Child

2012 ◽  
Vol 32 (2) ◽  
pp. 162-166 ◽  
Author(s):  
Jeong Yeal Ahn ◽  
Yiel Hea Seo ◽  
Pil Whan Park ◽  
Kyung Hee Kim ◽  
Mi Jung Park ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Korean Child ◽  
Large B Cell

scholarly journals Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Karsten Kleo ◽  
Lora Dimitrova ◽  
Elisabeth Oker ◽  
Nancy Tomaszewski ◽  
Erika Berg ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document